US2022211696A1PendingUtilityA1
Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor
Est. expirySep 7, 2032(~6.2 yrs left)· nominal 20-yr term from priority
Inventors:Deepak SampathChristian KleinWayne FairbrotherSari L. Heitner EnschedeRod A. HumerickhouseAndrew W. RobertsJohn F. Seymour
A61K 39/395A61K 31/4375A61K 31/04A61K 31/505A61K 31/437A61K 2039/545A61K 31/02A61K 31/18A61K 31/45A61K 39/39558A61K 31/436A61K 31/33A61K 31/10A61K 31/63A61K 2039/585A61K 31/496C07K 2317/24A61P 35/00C07K 2317/73C07K 16/2887A61P 35/02A61P 43/00
78
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
Claims
exact text as granted — not AI-modified1 . A method for the treatment of a cancer in a human in need thereof comprising
administering to said human an effective amount of a GA101 antibody or 2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazin-1-yl)-N-(3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenylsulfonyl)benzamide or a pharmaceutically acceptable salt thereof for one or more dosing periods, followed by co-administering an effective amount of said GA101 antibody and 2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazin-1-yl)-N-(3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenylsulfonyl)benzamide or a pharmaceutically acceptable salt thereof for one or more dosing periods.
2 .- 29 . (canceled)Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.